GlassScriptPhysician profile
James A Goldstein
NPI 1407830847
$2,058.18
in general payments reported to CMS, 2019-2025
21 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $26.35 · 2023: $145 · 2024: $551 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $572.65 | 2019-2025 | Cds - Mct/Cem Monitoring, General - Therapies, Emblem Mri S-Icd |
| Astrazeneca Pharmaceuticals LP | $215.13 | 2019-2025 | Wainua |
| Abbott Laboratories | $200.14 | 2019-2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $172.88 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $163.77 | 2024-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.45 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.43 | 2023-2025 | Lifevest |
| Spectrawave, INC | $95.81 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Alnylam Pharmaceuticals INC. | $66.21 | 2024-2025 | Onpattro |
| Amgen INC. | $53.32 | 2024-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $40.37 | 2020-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $30.80 | 2025 | |
| Kestra Medical Technology Services, INC. | $29.73 | 2025 | Assure Wcd |
| Pfizer INC. | $29.10 | 2025 | |
| Cook Medical LLC | $27.04 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $21.46 | 2025 | |
| Abiomed | $19.77 | 2025 | |
| Novo Nordisk INC | $19.54 | 2025 | Wegovy |
| Baxter Healthcare | $14.98 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $14.60 | 2025 | Attruby |
| Vivaquant INC, Dba Rhythm Express | $9.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,730,958.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.